Epidemiologic and Prognostic Implications of Silent Atrial Fibrillation

摘要

Normal 0 false false false IT JA X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Tabella normale"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Cambria","serif"; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-ansi-language:IT; mso-fareast-language:IT;} Atrial fibrillation (AF) in the most common cardiac arrhythmia, and is associated with an increased risk of thromboembolic events. Silent AF is an asymptomatic form of AF incidentally diagnosed during a routine test or manifesting as an arrhythmia-related complication. Although recent trials have clearly demonstrated that patients with sub-clinical AF are at increased risk of stroke, the real incidence of this form of AF is still unknown. In fact, studies about silent AF had been performed only in specific subgroups of patients such as those with implantable cardiac devices, with recent cryptogenic stroke or transient ischemic attack, and recently undergoing AF ablation. Continuous ECG-monitoring in patients without implantable cardiac devices may improve silent AF detection but its cost-effectiveness actually is not well established in all kind of patients. Moreover, recent data have revealed that only a small number of these patients may have sub-clinical AF within the month prior to their stroke suggesting a lack of temporal relationship between the stroke and the AF episode. This paper will review available data on different diagnostic tools for silent AF detection with a focus on their cost-effectiveness, analyzing the direct correlation between the arrhythmia and embolic events, and discussing areas of uncertainty where further research is required .